Matches in SemOpenAlex for { <https://semopenalex.org/work/W44459855> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W44459855 endingPage "12" @default.
- W44459855 startingPage "2509" @default.
- W44459855 abstract "There have been few reports on the efficacy or safety of combination therapy with carboplatin-paclitaxel plus bevacizumab(TC+Bev)in previously treated patients with non-small cell lung carcinoma(NSCLC).The objective of this study was to assess the efficacy and safety of TC+Bev as second-line therapy and beyond for previously treated NSCLC patients.A total of 17 patients previously treated with NSCLC at the Kitasato University Hospital between April 2010 and February 2012 were enrolled in this retrospective study. On day 1 all patients received a 200mg/m2 dose of paclitaxel by intravenous infusion over a 3-h period, followed by infusion of carboplatin at a dose corresponding to an AUC of 6.0 min mg/mL, and then by Bev at a dose of 15mg/m2. The treatment course was repeated every three or four weeks. Patients continued to receive Bev monotherapy every 3 weeks thereafter until evidence of disease progression or unacceptable toxicity developed.Median age: 60 years old(range 39-74 years old); gender: male/female, 6/11; PS 0-1/≥2, 17/0; clinical stage:III B/IV postoperative recurrence, 0/16/1; EGFR mutation status: positive/negative/unknown, 7/9/1; histological type: adenocarcinoma in all patients; median number of prior regimens: 3. 4(1-6); median number of cycles(induction phase): 3(1-6). The objective response rate and disease control rate were 17. 6% and 70. 6%, respectively, and the median progression-free survival time was 4. 7 months. There were no treatment-related deaths, and the toxicities of the treatment regimen were acceptable.TC+Bev therapy exhibits activity in previously treated NSCLC patients and has acceptable toxicity. Further study is warranted to confirm our results." @default.
- W44459855 created "2016-06-24" @default.
- W44459855 creator A5004024254 @default.
- W44459855 creator A5004383942 @default.
- W44459855 creator A5017038735 @default.
- W44459855 creator A5021722390 @default.
- W44459855 creator A5041253186 @default.
- W44459855 creator A5045155531 @default.
- W44459855 creator A5047466247 @default.
- W44459855 creator A5062029578 @default.
- W44459855 creator A5077430155 @default.
- W44459855 creator A5080980111 @default.
- W44459855 creator A5083748360 @default.
- W44459855 creator A5084247658 @default.
- W44459855 date "2012-12-01" @default.
- W44459855 modified "2023-10-16" @default.
- W44459855 title "[Efficacy of chemotherapy with carboplatin-paclitaxel plus bevacizumab for previously treated patients with advanced non-small cell carcinoma]." @default.
- W44459855 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23235169" @default.
- W44459855 hasPublicationYear "2012" @default.
- W44459855 type Work @default.
- W44459855 sameAs 44459855 @default.
- W44459855 citedByCount "0" @default.
- W44459855 crossrefType "journal-article" @default.
- W44459855 hasAuthorship W44459855A5004024254 @default.
- W44459855 hasAuthorship W44459855A5004383942 @default.
- W44459855 hasAuthorship W44459855A5017038735 @default.
- W44459855 hasAuthorship W44459855A5021722390 @default.
- W44459855 hasAuthorship W44459855A5041253186 @default.
- W44459855 hasAuthorship W44459855A5045155531 @default.
- W44459855 hasAuthorship W44459855A5047466247 @default.
- W44459855 hasAuthorship W44459855A5062029578 @default.
- W44459855 hasAuthorship W44459855A5077430155 @default.
- W44459855 hasAuthorship W44459855A5080980111 @default.
- W44459855 hasAuthorship W44459855A5083748360 @default.
- W44459855 hasAuthorship W44459855A5084247658 @default.
- W44459855 hasConcept C121608353 @default.
- W44459855 hasConcept C126322002 @default.
- W44459855 hasConcept C141071460 @default.
- W44459855 hasConcept C143998085 @default.
- W44459855 hasConcept C2776256026 @default.
- W44459855 hasConcept C2776694085 @default.
- W44459855 hasConcept C2777292972 @default.
- W44459855 hasConcept C2777802072 @default.
- W44459855 hasConcept C2778239845 @default.
- W44459855 hasConcept C2781182431 @default.
- W44459855 hasConcept C2781451048 @default.
- W44459855 hasConcept C29730261 @default.
- W44459855 hasConcept C71924100 @default.
- W44459855 hasConcept C90924648 @default.
- W44459855 hasConceptScore W44459855C121608353 @default.
- W44459855 hasConceptScore W44459855C126322002 @default.
- W44459855 hasConceptScore W44459855C141071460 @default.
- W44459855 hasConceptScore W44459855C143998085 @default.
- W44459855 hasConceptScore W44459855C2776256026 @default.
- W44459855 hasConceptScore W44459855C2776694085 @default.
- W44459855 hasConceptScore W44459855C2777292972 @default.
- W44459855 hasConceptScore W44459855C2777802072 @default.
- W44459855 hasConceptScore W44459855C2778239845 @default.
- W44459855 hasConceptScore W44459855C2781182431 @default.
- W44459855 hasConceptScore W44459855C2781451048 @default.
- W44459855 hasConceptScore W44459855C29730261 @default.
- W44459855 hasConceptScore W44459855C71924100 @default.
- W44459855 hasConceptScore W44459855C90924648 @default.
- W44459855 hasIssue "13" @default.
- W44459855 hasLocation W444598551 @default.
- W44459855 hasOpenAccess W44459855 @default.
- W44459855 hasPrimaryLocation W444598551 @default.
- W44459855 hasRelatedWork W2000174546 @default.
- W44459855 hasRelatedWork W2053778437 @default.
- W44459855 hasRelatedWork W2057246093 @default.
- W44459855 hasRelatedWork W2060251426 @default.
- W44459855 hasRelatedWork W2061440113 @default.
- W44459855 hasRelatedWork W2072767112 @default.
- W44459855 hasRelatedWork W2395106973 @default.
- W44459855 hasRelatedWork W2763599771 @default.
- W44459855 hasRelatedWork W4246343941 @default.
- W44459855 hasRelatedWork W84951532 @default.
- W44459855 hasVolume "39" @default.
- W44459855 isParatext "false" @default.
- W44459855 isRetracted "false" @default.
- W44459855 magId "44459855" @default.
- W44459855 workType "article" @default.